Literature DB >> 359212

Clinical pharmacokinetics of pethidine.

L E Mather, P J Meffin.   

Abstract

Pethidine is commonly used in single doses as a preoperative medication or in multiple doses as an analgesic. The clinical consequences of altered disposition are more likely to result from its analgesic use. Correlations between plasma pethidine concentration, analgesia and side effects such as respiratory depression, have been established, but considerable overlap exists between concentrations producing therapeutic and non-therapeutic effects. The current practice of intermittent pethidine administration (intravenous, intramuscular and oral) for analgesia results in fluctuations in pethidine plasma concentrations which are associated with incomplete pain relief and side effects. Continuous intravenous infusion of pethidine may avoid these difficulties. Changes in pethidine disposition have been observed in patients with liver disease and in the elderly. Measurement of plasma pethidine concentrations may be helpful as an aid to the management of such patients. In renal disease, metabolites may accumulate and cause side effects.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 359212     DOI: 10.2165/00003088-197803050-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  63 in total

1.  Letter: pharmacokinetics of meperidine in man.

Authors:  G Moore; R Nation
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

2.  Systemic availability of orally administered meperidine.

Authors:  L E Mather; G T Tucker
Journal:  Clin Pharmacol Ther       Date:  1976-11       Impact factor: 6.875

3.  The effect of low environmental temperature on the tranylcypromine-meperidine interaction in mice.

Authors:  P K Gessner; C C Clarke; M Adler
Journal:  J Pharmacol Exp Ther       Date:  1974-04       Impact factor: 4.030

4.  GLC determination of meperidine in blood plasma.

Authors:  T J Goehl; C Davison
Journal:  J Pharm Sci       Date:  1973-06       Impact factor: 3.534

5.  Influence of age on pain relief from analgesics. A study of postoperative patients.

Authors:  J W Bellville; W H Forrest; E Miller; B W Brown
Journal:  JAMA       Date:  1971-09-27       Impact factor: 56.272

6.  Disposition of meperidine in pregnancy.

Authors:  D Morgan; G Moore; J Thomas; E Triggs
Journal:  Clin Pharmacol Ther       Date:  1978-03       Impact factor: 6.875

7.  The physiological disposition and fate of meperidine (demerol) in man and a method for its estimation in plasma.

Authors:  J J BURNS; B L BERGER; P A LIEF; A WOLLACK; E M PAPPER; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1955-07       Impact factor: 4.030

8.  Meperidine metabolites: identification of N-hydroxynormeperidine and a hydroxy-methoxy derivative of meperidine in biological fluids.

Authors:  W G Stillwell; C S Myran; J T Stewart
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1976-08

9.  Metabolites of meperidine in the fetal and maternal serum.

Authors:  J C Morrison; W D Whybrew; S I Rosser; E T Bucovaz; W L Wiser; S A Fish
Journal:  Am J Obstet Gynecol       Date:  1976-12-15       Impact factor: 8.661

10.  A cross-over comparison of the effect of morphine, pethidine, pentazocine, and phenazocine on biliary pressure.

Authors:  G Economou; J N Ward-McQuaid
Journal:  Gut       Date:  1971-03       Impact factor: 23.059

View more
  28 in total

1.  Possible roles of normeperidine and hyponatremia in a postoperative death.

Authors:  W C Appel
Journal:  CMAJ       Date:  1987-11-15       Impact factor: 8.262

Review 2.  Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships.

Authors:  B N Swerdlow; F O Holley
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

Review 3.  Pharmacokinetics of opioids in renal dysfunction.

Authors:  G Davies; C Kingswood; M Street
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 4.  Rectal drug administration: clinical pharmacokinetic considerations.

Authors:  A G de Boer; F Moolenaar; L G de Leede; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

5.  Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models.

Authors:  Sven Björkman
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-08       Impact factor: 2.745

6.  Patient-controlled analgesic therapy, Part II: Individual analgesic demand and analgesic plasma concentrations of pethidine in postoperative pain.

Authors:  A Tamsen; P Hartvig; C Fagerlund; B Dahlström
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

7.  Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods.

Authors:  A Tamsen; P Hartvig; C Fagerlund; B Dahlström
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

8.  Clinical and pharmacokinetic aspects of the combination of meperidine and prilocaine for spinal anaesthesia.

Authors:  P Tauzin-Fin; P Maurette; G Vincon; D Hecquet; M C Houdek; F Bonnet
Journal:  Can J Anaesth       Date:  1992-09       Impact factor: 5.063

9.  Maternal kinetics and transplacental passage of pethidine during labour.

Authors:  G Tomson; R I Garle; B Thalme; H Nisell; L Nylund; A Rane
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

10.  Patient-controlled analgesic therapy, Part III: pharmacokinetics and analgesic plasma concentrations of ketobemidone.

Authors:  A Tamsen; U Bondesson; B Dahlström; P Hartvig
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.